1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

ESMO 23: Amgen's Lumakras/Vectibix Combo Clinches Colorectal Cancer Win

 
• By Kevin Grogan

The higher dose of Amgen's Lumakras combined with Vectibix has demonstrated significant superiority in progression-free survival over investigator's choice of therapy in KRAS G12C-mutated metastatic colorectal cancer but the discussant at the combo's ESMO presentation wants to see overall survival data before getting too excited.

ESMO Lumakras CRC
Filippo Pietrantonio presents CodeBreak 300 at the Madrid meeting • Source: ESMO

Amgen, Inc. caused a stir at the European Society for Medical Oncology meeting in Madrid with promising data for its small-cell lung cancer offering tarlatamab but the reception for a late-stage study looking at a combination of its KRAS G12C inhibitor Lumakras and Vectibix for colorectal cancer was a bit cooler.

Having revealed in August that CodeBreak 300, a 160-patient Phase III trial evaluating two doses of Lumakras (sotorasib) combined with Amgen’s own anti-EGFR antibody Vectibix (panitumumab), in third-line KRAS G12C-mutated metastatic colorectal cancer (mCRC) met its primary endpoint of progression-free survival (PFS), the full dataset was presented at an ESMO presidential session on 22 October and simultaneously published in the New England Journal of Medicine. After a follow-up of 7.8 months, median PFS was 5.6 months and 3.9 months with Lumkakras 960mg and 240mg plus Vectibix respectively, versus 2

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

More from Therapy Areas

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.